Background: Nanotechnology has provided substantial benefits in drug delivery, especially
in the treatment of dermatological diseases. Psoriasis is a chronic inflammatory skin disease in which
topical delivery of antipsoriatic agents is considered the first line treatment.
Objective: To investigate whether the encapsulation of the synthetic retinoid tazarotene in a nanocarrier
based on jojoba oil would decrease its irritation potential and clinically improve its therapeutic outcome
in psoriatic patients.
Method: A microemulsion system based on jojoba wax and labrasol/plurol isostearique was prepared
Results: The selected formula displayed spherical morphology, particle size of 15.49±2.41 nm, polydispersity
index of 0.20 ±0.08, negative charge and low viscosity. The microemulsion provided two folds
increase in skin deposition of tazarotene, correlating with higher reduction in psoriatic patients PASI
scores after treatment (68% reduction in PASI scores versus 8.96% reduction with the marketed gel).
No irritation was encountered in patients using microemulsion, with redness and inflammation reported
with the marketed gel-treated patients.
Conclusion: Jojoba oil microemulsion proved to be advantageous in reducing the irritancy of tazarotene,
enhancing its skin deposition and achieving better therapeutic outcome in psoriatic patients.